Cystic Papillary Thyroid Carcinoma: A Case Report

Darwin Totesora; Ma. Theresa Chua-Agcaoili

doi:10.15605/jafes.034.02.14

Authors

Darwin Totesora The Medical City http://orcid.org/0000-0002-5219-6442
Ma. Theresa Chua-Agcaoili The Medical City

DOI:

https://doi.org/10.15605/jafes.034.02.14

Keywords:

cystic papillary thyroid carcinoma, HBME-1, papillary thyroid carcinoma

Abstract

The malignant potential of cystic nodule(s) should never be overlooked in certain select patients even if it carries a low chance of malignancy. The diagnosis of PTC relies primarily on the typical nuclear features, however in cases of histologic uncertainty, immunohistochemical stains such as HBME-1 may be used to help classify unusual presentations of PTC. Treatment and monitoring of Cystic Papillary Thyroid Carcinoma follows the conventional guideline on solid PTC.

Downloads

Download data is not yet available.

Author Biographies

Darwin Totesora, The Medical City

Fellow-in-training

Section of Endocrinology, Diabetes and Metabolism

Department of Medicine

Ma. Theresa Chua-Agcaoili, The Medical City

Consultant

Section of Endocrinology, Diabetes and Metabolism

Department of Medicine

References

Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133. https://www.ncbi.nlm.nih.gov/pubmed/26462967. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739132. https://doi.org/10.1089/thy.2015.0020.

Raboca-Carlos J, Kho SA, et al. The Philippine Thyroid Disease Study (PhilTiDes1): Prevalance of thyroid disorders among adults in the Philippines. J ASEAN Fed of Endocr Soc. 2012;27(1): 27-33. https://doi.org/10.15605/jafes.027.01.04.

Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer data base report on 53, 856 cases of thyroid carcinoma treated in the US from 1985-1995. Cancer. 1998;83(12):2638-48. https://www.ncbi.nlm.nih.gov/pubmed/9874472. https://doi.org/10.1002/(sici)10970142(19981215)83:12<2638::aidcncr31>3.0.co;2-1.

Lo TE, Uy AT, Maningat PD. Well-differentiated thyroid cancer: The Philippine General Hospital experience. Endocrinol Metab (Seoul). 2016;31(1):72-9. https://www.ncbi.nlm.nih.gov/pubmed/26754584. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803565. https://doi.org/10.3803/EnM.2016.31.1.72.

Ross D. Cystic thyroid nodules. UpToDate. https://www.uptodate.com/contents/cystic-thyroid-nodules.

de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, Mazzaferri EL. Cystic thyroid nodules. The dilemma of malignant lesions. Arch Intern Med. 1990;150(7):1422-7. https://www.ncbi.nlm.nih.gov/pubmed/2196027. https://doi.org/10.1001/archinte.150.7.1422.

Pathology and genetics of tumors of the endocrine organs, 3rd ed. WHO classification of tumours, vol. 8, DeLellis RA, Lloyd RV, Heitz PU, ed.; 2004.

Hapke MR, Dehner LP, The optically clear nucleus: A reliable sign of papillary thyroid carcinoma of the thyroid. Am J Surg Pathol.1979;31(1):31-8. https://www.ncbi.nlm.nih.gov/pubmed/534382. https://doi.org/10.1097/00000478-197902000-00004.

Liu H and Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015;139(1):67-82. https://www.ncbi.nlm.nih.gov/pubmed/ 25549145. https://doi.org/10.5858/arpa.2014-0056-RA.

Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME-1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126(5):700-8. https://www.ncbi.nlm.nih.gov/pubmed/17050067. https://doi.org/10.1309/044V-86JN-2W3C-N5YB.

Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arsian A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci. 2016; 21:49.

https://www.ncbi.nlm.nih.gov/pubmed/27904595. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121990. https://doi.org/10.4103/1735-1995.183986.

Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of Papillary Thyroid Carcinoma: Utility of HBME-1 combined with CK19 immunohistostaining. Mod Pathol. 2006;19(12):1631-7. https://www.ncbi.nlm.nih.gov/pubmed/16998461. https://doi.org/10.1038/modpathol.3800705.

Patil VS, Vijayakumar A, Natikar N. Unusual presentation of cystic papillary thyroid carcinoma. Case Rep Endocrinol. https://www.ncbi.nlm.nih.gov/pubmed/23133761. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485764. https://doi.org/10.1155/2012/732715.

Baser B, Munjal VR, Roy MT. Papillary carcinoma of the thyroid with unusual presentation. Indian J Otolaryngol Head Neck Surg. 2015;67(suppl 1):145-8. https://www.ncbi.nlm.nih.gov/pubmed/25621272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298624. https://doi.org/10.1007/s12070-014-0746-y.

Pratinidhi S, Panda S, Das D. Papillary thyroid carcinoma presented as cystic neck mass: A rare presentation. Indian Journal of Clinical Practice. 2014; 24(4): 339-41. http://medind.nic.in/iaa/t13/i9/iaat13i9p339.pdf.

Rahmat F, Kumar A, Muthu AKM, Gopal NSR, Han SJ, Yahaya AS. Papillary thyroid carcinoma as a lateral neck cyst: A cystic metastatic node versus an ectopic thyroid tissue. Case Rep Endocrinol. 2018;2018:5198297. https://www.ncbi.nlm.nih.gov/pubmed/30420925. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211211. https://doi.org/10.1155/2018/5198297.